New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

James Beckerman, M.D., offers helpful tips on KPTV for reducing heart disease risk with easy, consistent actions like short bouts of exercise, proper rest and nutrition.

Lori Tam, M.D., talks with KATU about how hormonal changes can affect heart health and what women can do to reduce their risk.

Mike Murray, M.D., talks with KATU about the changes in winter sport-related injuries and offers helpful strategies to prevent breaks and fractures.

If you’ve been diagnosed with high blood pressure, there are lots of ways you can lower your blood pressure without prescription medications.

Providence honors the donors who have given the gift of life, health and hope to those in need.

Learn how Medicaid support 79 million Americans.

A new type of surgical treatment for patients with benign prostatic hyperplasia (BPH) uses the power of water delivered with robotic precision to provide long-lasting BPH relief

Providence honors the donors who have given the gift of life, health and hope to those in need.

Breanne Brown, M.D., demonstrated simple exercises on KATU’s “Family Matters” to help viewers incorporate movement into their daily routines.

Providence honors the donors who have given the gift of life, health and hope to those in need.

Justin Jin, M.D., shares guidance with KATU on how vaccination protects one another and supports the health of our community.

Dr. Elizabeth Lieberman was one of a select group of 15-20 U.S. surgeons invited to gain early experience with the enhanced software for the Zimmer Biomet ROSA with Optimize robot.

Providence Heart Clinic – Newberg recently hosted screenings for kids ages 12–18.

The Knights’ generosity is establishing new frontiers in cardiac care at Providence Heart Institute and Providence St. Vincent Medical Center.

Providence Holy Cross Medical Center has been named among America’s 50 Best Hospitals, marking the seventh straight year the hospital has been recognized for excellence and outstanding patient outcome

Jenna Kay, M.D., cardiologist with Providence Heart Institute, explains the signs, risks, and treatment options for this often-overlooked heart condition.

Cardiovascular disease remains the leading cause of death in the United States, and many risk factors develop quietly, underscoring the importance of being proactive about heart health.

The study may redefine care for many people at the earliest stage of their treatment.

At Providence Little Company of Mary Medical Center Torrance, we’re reimagining emergency care to better serve the growing needs of the South Bay.